MicuRx(SH:688373) Sou Hu Cai Jing·2025-09-25 02:01Core Viewpoint - Genie Pharma, the largest shareholder of Amgen Pharmaceuticals, has initiated a strong counteraction by proposing the removal of the chairman and two other directors, while also publicly soliciting voting rights to oppose several resolutions at the upcoming shareholder meeting [1][6]. Group 1: Shareholder Actions - Genie Pharma voted against multiple resolutions, including a capital increase proposal, at the upcoming shareholder meeting scheduled for 2025 [1]. - The proposal includes the removal of ZHENGYU YUAN (Yuan Zhengyu), the current chairman and general manager, along with two other directors, and the election of three new directors [1][6]. - Genie Pharma's actions are a response to perceived failures in governance and management, particularly regarding the company's financial performance and operational decisions [6][12]. Group 2: Financial Performance - Amgen Pharmaceuticals has reported significant financial losses since its IPO, with cumulative losses exceeding 1.3 billion yuan from 2021 to 2024 [6][9]. - The company's revenue has shown growth, from 7.66 million yuan in 2021 to 130 million yuan in 2024, but net profit losses have also increased, reaching 441 million yuan in 2024 [6][9]. - As of June 2025, the company's asset-liability ratio has risen to approximately 60%, with net assets declining by 74.19% since its listing [9]. Group 3: Strategic Concerns - Genie Pharma has raised concerns about the delayed progress of IPO fundraising projects, which has hindered the company's operational expectations [9]. - The company has faced challenges in meeting financing conditions, leading to a loss of financing capabilities [9]. - There are concerns regarding the strategic partnership with Haiqing Pharmaceuticals, which has faced regulatory penalties, raising questions about compliance and business viability [10][12].